Silver Book Fact

The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.

Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group. Forecasting Age-Related Macular Degeneration Through the Year 2050. JAMA Ophthalmol. 2009; 127(4): 533-40. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/422785

Reference

Title
Forecasting Age-Related Macular Degeneration Through the Year 2050
Publication
JAMA Ophthalmol
Publication Date
2009
Authors
Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group
Volume & Issue
Volume 127, Issue 4
Pages
533-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • Tele-ophthalmology
    Adequately trained general practitioners can screen for DR with 90% sensitivity using tele-ophthalmology.